A single infusion of Allogene Therapeutics‘ cell therapy ALLO-329 was followed by clinically meaningful improvements in skin scores in eight of 10 people with skin-predominant systemic sclerosis (SSc), a hard-to-treat autoimmune disease. The findings come from an ongoing Phase 1 clinical trial called RESOLUTION (NCT07085104), which is…
Discussion
Given that systemic sclerosis can affect their appearance, many people with the condition are open to dermocosmetic and aesthetic treatments, a survey found. Patients said they would prefer to discuss their plans with a rheumatologist (a doctor who specializes in diseases of the joints, muscles, and bones) before…
Discussion
An experimental oral therapy called ifetroban proved generally safe and was well tolerated in adults with systemic sclerosis (SSc) over one year of treatment, according to top-line findings from a Phase 2a clinical trial. The trial, called ASSIST-SSc study (NCT02682511), compared once-daily ifetroban against a placebo in 41…
Becoming educated and informed about scleroderma is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your scleroderma journey.
There is no cure for scleroderma yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
